The impact of targeted therapies in glioma has been modest. All the therapies that have
demonstrated a significant survival benefit for gliomas in Phase III trials, including radiation …

Activation of oncogenes and loss of tumour suppressors promote metabolic reprogramming
in cancer, resulting in enhanced nutrient uptake to supply energetic and biosynthetic …

Purpose: Isocitrate dehydrogenase (IDH) mutations in glioma patients confer longer survival
and may guide treatment decision making. We aimed to predict the IDH status of gliomas …

IDH1 mutations are common in low-grade gliomas and secondary glioblastomas and cause
overproduction of (R)-2HG.(R)-2HG modulates the activity of many enzymes, including some …

Cancer metabolism has long been equated with aerobic glycolysis, seen by early
biochemists as primitive and inefficient. Despite these early beliefs, the metabolic signatures …

This review summarizes clinical studies in which glutathione was measured in tumor tissue
from patients with brain, breast, gastrointestinal, gynecological, head and neck and lung …

The discovery of cancer-associated mutations in genes encoding key metabolic enzymes
has provided a direct link between altered metabolism and cancer. Advances in mass …

Genes encoding for isocitrate dehydrogenases 1 and 2, IDH1 and IDH2, are frequently
mutated in multiple types of human cancer. Mutations targeting IDH1 and IDH2 result in …

Background. Isocitrate dehydrogenase (IDH) mutation status has emerged as an important
prognostic marker in gliomas. Currently, reliable IDH mutation determination requires …

Glioblastoma is both the most common and lethal primary malignant brain tumor. Extensive
multiplatform genomic characterization has provided a higher-resolution picture of the …